Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis

Beneficial Microbes

Volumn 7, Issue 4, 2016, Pages 549-558

  Bastos, R W ^a   Pedroso, S H S P ^a   Vieira, A T ^a   Moreira, L M C ^a   Franca C S ^a   Cartelle, C T ^a   Arantes, R M E ^a   Generoso, S V ^a   Cardoso, V N ^a   Neves, M J ^b   Nicoli, J R ^a   Martins, F S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTRO DE DESENVOLVIMENTO DA TECNOLOGIA NUCLEAR   (Brazil)

Author keywords

Chemotherapy; Mucositis; Oxidative stress; Probiotic; Saccharomyces cerevisiae UFMG A 905

Indexed keywords

IRINOTECAN; PROBIOTIC AGENT; SC 905; UNCLASSIFIED DRUG; CAMPTOTHECIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIVISION; CELL VIABILITY; CONTROLLED STUDY; ENTEROPATHY; FUNGAL STRAIN; GOBLET CELL; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; IRINOTECAN INDUCED MUCOSITIS; MALE; MICROFLORA; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; SACCHAROMYCES CEREVISIAE; WEIGHT REDUCTION; YEAST; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DIET THERAPY; DISEASE MODEL; INTESTINE ABSORPTION; JEJUNUM; LIPID PEROXIDATION; PATHOLOGY; SMALL INTESTINE;

ANIMALS; CAMPTOTHECIN; DISEASE MODELS, ANIMAL; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, SMALL; JEJUNUM; LIPID PEROXIDATION; MALE; MICE; MUCOSITIS; OXIDATIVE STRESS; PROBIOTICS; SACCHAROMYCES CEREVISIAE; WEIGHT LOSS;

EID: 84988847936     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2015.0190     Document Type: Article

References (45)

1. Al-Dasooqi, N., Bowen, J.M., Gibson, R.J., Logan, R.M., Stringer, A.M. and Keefe, D.M., 2011. Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. International Journal of Experimental Pathology 92: 357-365.
2. Alimonti, A., Gelibter, A., Pavese, I., Satta, F., Cognetti, F., Ferretti, G., Rasio, D., Vecchione, A. and Di Palma, M., 2004. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treatment Reviews 30: 555-562.
3. Arifa, R.D., Madeira, M.F., de Paula, T.P., Lima, R.L., Tavares, L.D., Menezes-Garcia, Z., Fagundes, C.T., Rachid, M.A., Ryffel, B., Zamboni, D.S., Teixeira, M.M. and Souza, D.G., 2014. Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice. American Journal of Pathology 184: 2023-2034.
4. Bowen, J.M., Stringer, A.M., Gibson, R.J., Yeoh, A.S., Hannam, S. and Keefe, D.M., 2007. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biology & Therapy 6: 1449-1454.
5. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Analytical Biochemistry 72: 248-254.
6. Brandi, G., Dabard, J., Raibaud, P., Di Battista, M., Bridonneau, C., Pisi, A.M., Morselli Labate, A.M., Pantaleo, M.A., De Vivo, A. and Biasco, G., 2006. Intestinal microflora and digestive toxicity of irinotecan in mice. Clinical Cancer Research 12: 1299-1307.
7. Brestoff, J.R. and Artis, D., 2013. Commensal bacteria at the interface of host metabolism and the immune system. Nature Immunology 14: 676-684.
8. Buccigrossi, V., Laudiero, G., Russo, C., Miele, E., Sofia, M., Monini, M., Ruggeri, F.M. and Guarino, A., 2014. Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PloS One 9: e99830.
9. Cesaro, S., Chinello, P., Rossi, L. and Zanesco, L., 2000. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Supportive Care in Cancer 8: 504-505.
10. Chen, S., Yueh, M.F., Bigo, C., Barbier, O., Wang, K., Karin, M., Nguyen, N. and Tukey, R.H., 2013. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proceedings of the National Academy of Sciences of the USA 110: 19143-19148.
11. De Freitas Cuba, L., Salum, F.G., Cherubini, K. and de Figueiredo, M.A., 2015. Antioxidant agents: a future alternative approach in the prevention and treatment of radiation-induced oral mucositis? Alternative Therapies in Health and Medicine 21: 36-41.
12. Draper, H.H. and Hadley, M., 1990. Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology 186: 421-431.
13. Duman, D.G., Kumral, Z.N., Ercan, F., Deniz, M., Can, G. and Caglayan Yegen, B., 2013. Saccharomyces boulardii ameliorates clarithromycin-and methotrexate-induced intestinal and hepatic injury in rats. British Journal of Nutrition 110: 493-499.
14. Ellman, G.L., 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70-77.
15. Flieger, D., Klassert, C., Hainke, S., Keller, R., Kleinschmidt, R. and Fischbach, W., 2007. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72: 10-16.
16. Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO working group on draftingguidelines for the evaluation of probiotics in food. Available at: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
17. Generoso, S.V., Viana, M., Santos, R., Martins, F.S., Machado, J.A., Arantes, R.M., Nicoli, J.R., Correia, M.I. and Cardoso, V.N., 2010. Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Archives of Microbiology 192: 477-484.
18. Gibson, R.J. and Stringer, A.M., 2009. Chemotherapy-induced diarrhoea. Current Opinion Support Palliat Care 3: 31-35.
19. Gibson, R.J., Bowen, J.M., Inglis, M.R., Cummins, A.G. and Keefe, D.M., 2003. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. Journal of Gastroenterology and Hepatology 18: 1095-1100.
20. Ishii, Y., Sugimoto, S., Izawa, N., Sone, T., Chiba, K. and Miyazaki, K., 2014. Oral administration of Bifidobacterium breve attenuates UV-induced barrier perturbation and oxidative stress in hairless mice skin. Archives of Dermatological Research 306: 467-473.
21. Javle, M.M., Cao, S., Durrani, F.A., Pendyala, L., Lawrence, D.D., Smith, P.F., Creaven, P.J., Noel, D.C., Iyer, R.V. and Rustum, Y.M., 2007. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clinical Cancer Research 13: 965-971.
22. Justino, P.F., Melo, L.F., Nogueira, A.F., Costa, J.V., Silva, L.M., Santos, C.M., Mendes, W.O., Costa, M.R., Franco, A.X., Lima, A.A., Ribeiro, R.A., Souza, M.H. and Soares, P.M., 2014. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. British Journal of Nutrition 111: 1611-1621.
23. Kaushal, D. and Kansal, V.K., 2012. Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum alleviates age-inflicted oxidative stress and improves expression of biomarkers of ageing in mice. Molecular Biology Reports 39: 1791-1799.
24. Kehrer, D.F., Sparreboom, A., Verweij, J., de Bruijn, P., Nierop, C.A., van de Schraaf, J., Ruijgrok, E.J. and De Jonge, M.J., 2001. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clinical Cancer Research 7: 1136-1141.
25. Kweekel, D., Guchelaar, H.J. and Gelderblom, H., 2008. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treatment Reviews 34: 656-669.
26. Liong, M.T., 2008. Safety of probiotics: translocation and infection. Nutrition Reviews 66: 192-202.
27. Logan, R.M., Stringer, A.M., Bowen, J.M., Yeoh, A.S., Gibson, R.J., Sonis, S.T. and Keefe, D.M., 2007. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews 33: 448-460.
28. Maioli, T.U., De Melo Silva, B., Dias, M.N., Paiva, N.C., Cardoso, V.N., Fernandes, S.O., Carneiro, C.M., Dos Santos Martins, F. and De Vasconcelos Generoso, S., 2014. Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. Journal of Negative Results in Biomedicine 13: 6.
29. Martins, F.S., Elian, S.D., Vieira, A.T., Tiago, F.C., Martins, A.K., Silva, F.C., Souza, E.L., Sousa, L.P., Araújo, H.R., Pimenta, P.F., Bonjardim, C.A., Arantes, R.M., Teixeira, M.M. and Nicoli, J.R., 2011. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. International Journal of Medical Microbiology 301: 359-364.
30. Martins, F.S., Nardi, R.M., Arantes, R.M., Rosa, C.A., Neves, M.J. and Nicoli, J.R., 2005. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. Journal of General and Applied Microbiology 51: 83-92.
31. Martins, F.S., Rodrigues, A.C., Tiago, F.C., Penna, F.J., Rosa, C.A., Arantes, R.M., Nardi, R.M., Neves, M.J. and Nicoli, J.R., 2007. Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice. Journal of Medical Microbiology 56: 352-359.
32. Mishra, V., Shah, C., Mokashe, N., Chavan, R., Yadav, H. and Prajapati, J., 2015. Probiotics as potential antioxidants: a systematic review. Journal of Agricultural and Food Chemistry 63: 3615-3626.
33. Pedroso, S.H., Vieira, A.T., Bastos, R.W., Oliveira, J.S., Cartelle, C.T., Arantes, R.E., Soares, P.G., Generoso, S.V., Cardoso, V.N., Teixeira, M.M., Nicoli, J.R. and Martins, F.S., 2015. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161: 1950-1960.
34. Pico, J.L., Avila-Garavito, A. and Naccache, P., 1998. Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting. Oncologist 3: 446-451.
35. Pommier, Y., 2006. Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer 6: 789-802.
36. Sezer, A., Usta, U. and Cicin, I., 2009. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Medical Oncology 26: 350-357.
37. Stringer, A.M., Gibson, R.J., Bowen, J.M., Logan, R.M., Ashton, K., Yeoh, A.S., Al-Dasooqi, N. and Keefe, D.M., 2009a. Irinotecaninduced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. International Journal of Experimental Pathology 90: 489-499.
38. Stringer, A.M., Gibson, R.J., Logan, R.M., Bowen, J.M., Yeoh, A.S., Laurence, J. and Keefe, D.M., 2009b. Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemotherapy and Pharmacology 64: 123-132.
39. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T. and Kamataki, T., 1998. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemotherapy and Pharmacology 42: 280-286.
40. Tiago, F.C., Martins, F.S., Souza, E.L., Pimenta, P.F., Araujo, H.R., Castro, I.M., Brandão, R.L. and Nicoli, J.R., 2012. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. Journal of Medical Microbiology 61: 1194-1207.
41. Tiago, F.C., Porto, B.A., Ribeiro, N.S., Moreira, L.M., Arantes, R.M., Vieira, A.T., Teixeira, M.M., Generoso, S.V., Nascimento, V.N., Martins, F.S. and Nicoli, J.R., 2015. Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease. Beneficial Microbes 6: 807-815.
42. Vieira, A.T., Teixeira, M.M. and Martins, F.S., 2013. The role of probiotics and prebiotics in inducing gut immunity. Frontiers in Immunology 4: 445.
43. Wallace, B.D., Wang, H., Lane, K.T., Scott, J.E., Orans, J., Koo, J.S., Venkatesh, M., Jobin, C., Yeh, L.A., Mani, S. and Redinbo, M.R., 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330: 831-835.
44. Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F., 2007. Chemically induced mouse models of intestinal inflammation. Nature Protocols 2: 541-546.
45. Zwielehner, J., Lassl, C., Hippe, B., Pointner, A., Switzeny, O.J., Remely, M., Kitzweger, E., Ruckser, R. and Haslberger, A.G., 2011. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PloS One 6: e28654.